The largest shareholder of Kakao Healthcare, a subsidiary of Kakao, will change to CHA CareS of CHA Bio Group.
Kakao Healthcare is currently a 100% subsidiary of Kakao, but through Kakao's sale of existing shares, CHA CareS and CHA AI Healthcare, subsidiaries of CHA Bio Group, are set to secure 43.08% equity and become the largest shareholder. With this, CHA Bio Group will take control of Kakao Healthcare's management.
CHA Biotech disclosed on the 19th that it decided on a third-party paid-in capital increase of 30 billion won targeting Kakao. On the same day, Kakao also held a board meeting and disclosed that it resolved agenda items on changing Kakao Healthcare's equity structure and acquiring the paid-in capital increase.
According to the two companies, CHA CareS and CHA AI Healthcare (formerly Jayjun Cosmetic), subsidiaries of CHA Biotech, will invest 80 billion won through share purchases and participation in the paid-in capital increase to secure control of Kakao Healthcare.
A CHA Bio Group representative said the goal is to pursue strategic cooperation through an equity exchange between Kakao and CHA Bio Group. To strengthen its healthcare business, Kakao will acquire equity in CHA Biotech, which has global healthcare capabilities, while CHA Bio Group will acquire equity in Kakao Healthcare to advance Digital Healthcare technology, thereby strengthening the partnership.
Along with the equity exchange, the two companies will invest 50 billion won in Kakao Healthcare. First, CHA CareS and CHA AI Healthcare of CHA Bio Group will secure Kakao Healthcare equity from Kakao for 70 billion won. Of this, Kakao will use 30 billion won to acquire equity in CHA Biotech and 40 billion won to reinvest in Kakao Healthcare equity. CHA AI Healthcare will separately invest 10 billion won in Kakao Healthcare.
In addition, they will attract a 50 billion won investment from external investors. Through two transactions by the first quarter of next year, Kakao Healthcare's equity ratio is expected to change to ▲ CHA CareS and CHA AI Healthcare 43.08% ▲ Kakao 29.99% ▲ external investors 26.93%.
Once this fundraising is completed, Kakao Healthcare will secure a total of 100 billion won in business funds. With these funds, it plans to further strengthen competitiveness centered on ▲ the AI-based mobile health management solution "PASTA" ▲ medical data businesses such as "HRS" and "Haycorn" ▲ the hospital convenience service "Karechat."
Kakao Healthcare said it plans to expand online-offline linked businesses and accelerate global expansion through synergy with CHA Bio Group, which has medical and global expertise.
CHA Bio Group operates 77 medical service platforms in six countries, including the United States, Australia, Singapore, Japan, Indonesia, and Vietnam, and holds the largest medical network in the Asia-Pacific region. It plans to rapidly push the integration of smart healthcare technology into CHA Bio Group's global medical network, including CHA Hollywood Medical Center, Singapore Medical Group, and City Fertility, an Australian corporation in the infertility field.
CHA Bio Group said it expects to secure a unique position as a smart healthcare group by absorbing Kakao Healthcare's IT-based Digital Healthcare capabilities, including AI and big data. In particular, it expects Kakao Healthcare to contribute significantly to building connected healthcare that links living spaces, communities, and medical institutions, as well as to expanding senior healthcare services that the group is pursuing.